^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ALPP-targeted CAR-T immunotherapy

    Related drugs:
    12d
    Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=5, Terminated, TCRCure Biopharma Ltd. | N=24 --> 5 | Trial completion date: Aug 2027 --> Jan 2026 | Recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Dec 2025; Portfolio prioritization
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • TC-A101
    14d
    ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=5, Completed, Xinqiao Hospital of Chongqing | Recruiting --> Completed | Trial completion date: Jan 2026 --> Jul 2025
    Trial completion • Trial completion date • IO biomarker
    |
    cyclophosphamide • fludarabine IV
    14d
    Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=5, Completed, Xinqiao Hospital of Chongqing | Recruiting --> Completed | N=20 --> 5 | Trial completion date: May 2025 --> Aug 2025
    Trial completion • Enrollment change • Trial completion date
    |
    MSLN (Mesothelin)
    |
    cyclophosphamide • fludarabine IV • TC-A101
    6ms
    Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=24, Recruiting, TCRCure Biopharma Ltd.
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • TC-A101
    1year
    AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Arsenal Biosciences, Inc. | N=60 --> 19
    Enrollment change
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    cyclophosphamide • AB-1015
    over1year
    Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Xinqiao Hospital of Chongqing | Suspended --> Recruiting
    Enrollment open • CAR T-Cell Therapy • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    cyclophosphamide • TC-A101
    over1year
    ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=9, Recruiting, Xinqiao Hospital of Chongqing | Suspended --> Recruiting
    Enrollment open • CAR T-Cell Therapy • Metastases
    |
    cyclophosphamide • fludarabine IV
    over1year
    ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=9, Suspended, Xinqiao Hospital of Chongqing | Recruiting --> Suspended
    Trial suspension
    |
    cyclophosphamide • fludarabine IV
    over1year
    Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=20, Suspended, Xinqiao Hospital of Chongqing | Recruiting --> Suspended
    Trial suspension
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    cyclophosphamide • TC-A101
    over1year
    AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Arsenal Biosciences, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    cyclophosphamide • AB-1015
    over1year
    Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Xinqiao Hospital of Chongqing | Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> May 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
    Enrollment open • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    MSLN (Mesothelin)
    |
    cyclophosphamide • TC-A101
    over1year
    AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=60, Recruiting, Arsenal Biosciences, Inc. | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    cyclophosphamide • AB-1015